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ClearanceAge is considered themost important risk factor for Alzheimer's disease. Soluble amyloid-beta (Aβ) has been impli-
cated as the primary neurotoxic agent in Alzheimer's disease pathology. The link between aging and Aβ, however,
remains unclear. In this study, we aimed to investigate the evolution of soluble Aβ over various age groups in the
APP23 amyloidosis mouse model and correlate these changes to alterations in the levels of proteins involved in
Aβ production.We found a distinct patternwith an initial buildup of Aβwhich could be linked to an increase in am-
yloid precursor protein (APP). Following this increase, Aβ concentrations remained stable until a surge in Aβ1–42 at
18 months. This rise was followed by an increase in Aβ1–40 and overall Aβ levels. The rise in Aβ at later age did not
correlate to changes in the levels of APP, presenilin, and β-secretase and is suggested to result from a decrease in
clearance. The APP23model could provide an interesting tool for future research regarding aging and Aβ clearance.
© Elsevier B.V. All rights reserved.20151. Introduction
Dementia is one of the leading causes for dependence and disability in
later life. While 2–10% of all dementia cases develop before the age of 65,
the majority commences after 65. From the age of 65, the prevalence ac-
tually doubleswith every 5 year increment in age, increasing exponential-
ly to 40% ormore in people aged 85 years and older, making age themost
important risk factor for dementia [1]. Alzheimer's disease (AD) is the
most common cause of dementia, responsible for 50–75% of all dementias
[1]. This progressive, neurodegenerative disorder is neuropathologically
characterized by neuronal loss, gliosis, dystrophic neurites, amyloid
plaques, and neuroﬁbrillary tangles of hyperphosphorylated tau [2].
Based on the age of onset, AD can be subdivided into two subtypes:
early-onset AD (EOAD) and late-onset AD (LOAD). LOAD is the most fre-
quently occurring type of AD and has an age of onset of 65 years or older.
Although several genetic risk factors for LOAD have been identiﬁed in
genome-wide association studies, no clear cause for the disease
has been found. Consequently, LOAD is assumed to be a polygenic/s disease; EOAD, early-onset
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n Dam).multifactorial disorder and is also termed sporadic AD [3]. EOAD, on the
other hand, accounts for about 5–10% of all AD cases and is generally
caused bymutations in one of the following three genes: amyloid precur-
sor protein (APP) [4–6], presenilin 1 [7], and presenilin 2 [8,9]. Mutations
in these genes tend to lead to a characteristic younger age of onset, usually
between 35 and 65 years of age [10]. The three genes are connected by
one common feature, namely, they are all involved in the processing of
APP and the resulting production of the amyloid-beta (Aβ) peptide.
The Aβ peptide is produced by the sequential cleavage of APP, a type
I transmembrane protein, by β- and γ-secretase. Initially, APP is cleaved
by β-secretase at the N-terminal end of the Aβ peptide, releasing an ex-
tracellular fragment, soluble APPβ [11]. Next, the remainingmembrane-
bound fragment, C-terminal fragmentβ (CTFβ), is cut into an intracellu-
lar fragment (amyloid intracellular domain) and an extracellular frag-
ment (Aβ) by the γ-secretase complex [12]. The resulting Aβ peptide
has been found to vary in length between 37 and 43 amino acids. The
most commonly produced Aβ species is Aβ40, but Aβ42 is more prone
to aggregation and considered to be the most pathogenic [13–16].
Presenilins (PS) have been indicated as the catalytic site of the γ-
secretase complex [17–21] and AD-related mutations in their genes
tend to cause a shift in Aβ production from Aβ1–40 to Aβ1–42 [22–25].
Whereas, mutations in the APP gene can affect Aβ production by either
shifting the Aβ production from Aβ1–40 to Aβ1–42 [26] or by increasing
the total amount of Aβ [27,28]. In addition to this genetic evidence
linking Aβ to AD, research has demonstrated the neurotoxic effects of
Aβ both in vitro and in vivo (as reviewed in [29]). The Aβ peptide is
106 L. Janssen et al. / Biochimica et Biophysica Acta 1862 (2016) 105–112also the main component of amyloid plaques, one of the key features of
AD pathology. Together, these ﬁndings have led to the development of
the amyloid cascade theory, which states that Aβ plays a central role
in AD pathology [30].
Initially, scientists believed the neuronal damage observed in AD
was caused by the deposition of amyloid into plaques in the brain, but
the plaque load correlates poorly with disease severity [31,32]. The
brain levels of soluble Aβ, on the other hand, do correlate well with
the amount of synaptic loss and cognitive deﬁcits [33–35]. Therefore,
the current predominant theory states that soluble aggregates of Aβ
are the primary neurotoxic agents in AD. In this study, we aimed to fur-
ther explore the relationship between the Aβ pathology and aging [36].
To this end, we examined the evolution in the soluble Aβ levels in the
APP23 mouse model for AD over a wide range of ages. The APP23
mouse model shows a 7-fold overexpression of human APP751 with
the K670M/N671L Swedish double mutation compared to the levels of
endogenous murine APP [37]. This Swedish mutation renders APP
more accessible to β-secretase and gives rise to an overall increase in
Aβ production [28]. The ﬁrst scarce amyloid plaques in this model ap-
pear at the age of 6 months, and the ﬁrst cognitive deﬁcits have been
observed as early as 3 months of age [37,38]. We investigated whether
the changes in soluble Aβ levels also correlated with these previously
observed changes in pathology and symptomatology. Finally, we also
explored if alterations in soluble Aβ levels could be correlated to chang-
es in the levels of proteins involved in Aβ production, i.e. APP, β- and γ-
secretase.
2. Materials and methods
2.1. Animals
Male heterozygous (HET) APP23 mice, overexpressing human
APP751 carrying the Swedish double mutation (K670M/N671L) [37],
were used for all experiments. Their male wild-type (WT) littermates
were included as a control group. Genotypes were determined through
PCR. All mice were bred within our facilities on a C57Bl/6 J background
and group-housed in standard mouse cages under conventional labora-
tory conditions with a 12:12 h light–dark cycle (light on at 8:00 AM,
light off at 8:00 PM), constant room temperature (22 ± 2 °C), humidity
level (55 ± 5%), and food and water available ad libitum. Based on
established milestones in the progression of AD pathology within the
model (e.g. ﬁrst appearance of plaques, cognitive deﬁcits), six age
groups were selected for the study: 1.5, 3, 6, 12, 18, and 24 months
[39]. Experiments were conducted in accordancewith the European Di-
rective (2010/63/EU) on the protection of animals used for experimen-
tal and other scientiﬁc purposes, and the Animal Ethics Committee of
the University of Antwerp approved all procedures.
2.2. Tissue collection
Animals were euthanized at the desired age through cervical dislo-
cation. The brain was harvested and dissected on ice into three parts:
two hemi-forebrains and the cerebellum (the olfactory bulbs were
discarded). After dissection, the brains were immediately stored at
−80 °C until use.
2.3. Protein extraction
Hemi-forebrains were thawed on ice and weighed to determine the
wet weight prior to extraction. Next, 900 μl of ice-cold TNT-buffer
[50 mM Tris-base (Thermo Fisher Scientiﬁc), 150 mM NaCl, 0.1% Triton
X-100, 1 mM phenylmethylsulfonyl ﬂuoride, 2 mM 1,10-Phenanthroline
Monohydrate (Merck Millipore), 1X protease inhibitor cocktail (Sigma–
Aldrich), pH7.40]was added. The tissuewas carefullymechanically disso-
ciated using a 1-ml syringe, followed by further ﬁner dissociation with a
1-ml syringe and 20 gauge needle and with a 1-ml pipet. Another900 μl of ice-cold TNT-buffer was added and the sample was centrifuged
for 30min at 25,000 RCF to pellet cell debris, cellular membranes, and or-
ganelles. The supernatantwas collected and centrifuged a second time for
30 min at 25,000 RCF. The resulting supernatant contained the protein
fraction from the soluble subcellular compartment, still soluble after
25,000 RCF centrifugation, and will hereafter be referred to as the soluble
fraction. The supernatant was collected, brieﬂy sonicated, and stored at
−20 °C. The pellet from the ﬁrst centrifugation step was resuspended
in 900 μl cold RIPA-buffer [50 mM Tris-base (Thermo Fisher Scientiﬁc),
150 mM NaCl, 0.5% Triton X-100, 1 mM Ethylenediaminetetraacetic
acid, 3% SDS, 1% deoxycholate, 1 mM phenylmethylsulfonyl ﬂuoride,
2 mM 1,10-Phenanthroline Monohydrate (MerckMillipore), 1X protease
inhibitor cocktail (Sigma–Aldrich), pH 7.40]. The resuspended sample
was ﬁrst dissociated vigorously with a 1-ml pipet. Then, another 900 μl
of RIPA-bufferwas added and the samplewas vortexed for 20 s. The sam-
ple was placed on a rotating platform for 15 min at 4 °C and centrifuged
for 30 min at 25,000 RCF. The resulting pellet contains the insoluble frac-
tion andwas stored at−20 °C. The supernatantwas centrifuged a second
time for 30 min at 25,000 RCF. The ﬁnal supernatant contained the
membrane-bound protein fraction and was again brieﬂy sonicated and
stored at−20 °C. Information on the evaluation of the separation in the
various subcellular fractions can be found in the supplementary data.
2.4. Bicinchoninic acid protein assay
The overall protein content in the protein extracts was determined
with the bicinchoninic acid (BCA) protein assay. The standard micro-
plate procedure was used according to the manufacturer's instructions
(ThermoScientiﬁc Pierce). All sampleswere diluted towithin the detec-
tion limits of the test, and 25 μl of the diluted samples was pipetted in
duplicate into the microplate. Next, 200 μl of working reagent was
added to each well and the plate was placed on a plate shaker for 30 s.
After incubation for 30min at 37 °C, the plate was cooled and the absor-
bance was measured on a plate reader at 550 nm. This test was per-
formed as a quality control for the reproducible and efﬁcient
execution of the extraction protocol and to ensure equal amounts of
total protein were loaded on the gel for SDS-PAGE.
2.5. ELISA
The concentration of Aβ1–x, Aβ1–40, and Aβ1–42 in the soluble protein
fractionwas determined by ELISAmeasurements using the human amy-
loid β (1–x) assay kit, the human amyloid β (1–40) assay kit, and the
human amyloid β (1–42) assay kit (IBL International). All samples
were diluted towithin the detection limits of the test and analyzed in du-
plicate according to themanufacturer's instructions. The amyloidβ (1–x)
assay detects all Aβ variants with an intact N-terminus and a length of
more than 16 amino acids. The amyloid β (1–40) assay shows ≤0.1%
cross-reactivity with other human Aβ species, but does show 16.3%
cross-reactivity with endogenous Aβ1–40. The amyloid β (1–42) assay
shows ≤0.1% cross-reactivity with other human Aβ species and endoge-
nous Aβ. The following sample sizes were used for the various age
groups: 1.5 months (n = 9), 3 months (n = 10), 6 months (n = 10),
12 months (n = 11), 18 months (n = 10), 24 months (n = 8 for Aβ1–
x measurements and n = 9 for other ELISA measurements).
2.6. SDS-PAGE and Western blotting
The membrane-bound protein fraction was thawed and all samples
were diluted to the same total protein concentration based on the BCA
assay results. NuPAGE® LDS Sample Buffer and reducing agent were
added to the samples which were subsequently heated to 95 °C for
10 min for denaturing, reducing SDS-PAGE. A constant amount of total
protein was loaded on NuPage® 4–12% Bis-Tris gels (Life Technologies).
Each gel contained at least one sample of each age group to allow for rel-
ative quantiﬁcation and to minimize inter-test variation. The gels were
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at 200 V. All gelswere run in duplicate. After electrophoresis, the proteins
were blotted for 1 h to Immobilon®-PSQ membrane (Millipore) in the
XCell II™ Blot Module (Life Technologies) using the standard
manufacturer's protocol. After blotting, the membranes were blocked
for 2 h in Tris-buffered saline with 0.1% tween-20 and 5% milk. Next,
themembraneswere incubated overnight at 4 °C in the sameblock buffer
with primary antibody. Three primary antibodies were used: mouse
monoclonal anti-Aβ1–16 (diluted 1/2000, 6E10, Covance), rabbit mono-
clonal anti-PS1 (diluted 1/5000, EP2000Y, Novus biologicals), and rabbit
monoclonal anti-beta-site APP-cleaving enzyme 1 (BACE1) (diluted 1/
5000, EPR3956, Novus biologicals). Following overnight incubation, the
membranes were washed with Tris-buffered saline with 0.1% tween-20
and incubated for 1 h at room temperature in block bufferwith horserad-
ish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Dako).
After a ﬁnal wash step, the membrane was treated with the
SuperSignal™West Femto Chemiluminescent Substrate (Thermo Fisher
Scientiﬁc) to visualize the protein bands. Blots were imaged with the
G:Box imager equipped with Genesnap software (Syngene) and ana-
lyzed with the Image Studio Lite v4.0 software (Li-Cor). PS1 and
BACE1 levels were determined for 7 mice per genotype in each age
group. For APP and CTFβ, the sample size was 8 mice per group, with
the exception of the 12 month group which contained 9 mice.
2.7. Statistical analysis
Due to the relatively small size of the test groups, non-parametrical
statistical analyses with exact signiﬁcance values were used for all
group comparisons. Comparisons between the genotype groups were
performed using the independent-samplesMann–Whitney U test. Differ-
ences between the various age groups within the HET group were evalu-
atedwith the independent-samples Kruskal–Wallis test. Post hoc analysis
between speciﬁc age groups was performed using the independent-
samples Mann–Whitney U test with a Bonferroni correction for multiple
comparisons (signiﬁcance level p b 0.0033). All p-values compared to
this Bonferroni-corrected signiﬁcance level will be marked throughout
the text as pbon. Outliers with a high coefﬁcient of variation (≥20%) be-
tween duplicate measurements were excluded from statistical analysis.
This resulted in the exclusion of one WT and one HET from the 6 month
group for the Aβ1–42 analysis and the Aβ1–42/Aβ1–40 ratio analysis. All sta-
tistical tests were performed using SPSS statistics software v22.0 (IBM).
All graphs were created using Graphpad Prism v5.03 (Graphpad). As
ELISA measurements of WT mice usually resulted in values below the
lower detection limit, the WT groups were omitted from all graphs
displaying ELISA results.
3. Results
3.1. The evolution in soluble Aβ1–x content
Initially, the overall Aβ levels in the soluble protein fraction were de-
termined for the various age and genotype groups using the human am-
yloid β (1–x) ELISA. Given the fact that the WT mice do not contain the
human APP construct, the Aβ1–x measurements resulted in background
levels below or near the test's lower detection limit. Consequently, a
clear difference could be observed between the WT and HET mice in all
age groups (p b 0.001). The Aβ levels of the HET animals also displayed
a distinct evolution over the various age groups (Fig. 1A, pb0.001). The
youngest age group, 1.5 months old, showed no signiﬁcant difference
with the 3-month-old group (p = 0.008), but did show signiﬁcantly
lower levels than all other age groups (pbon b 0.001). The Aβ levels of
the 3 month group displayed a borderline signiﬁcant difference with
the 6 months (pbon = 0.003) and 12 months (pbon = 0.002) age group
and a distinct difference with the 18 month and 24 month group
(pbon b 0.001). No signiﬁcant differences could be found between ages
of 6, 12, and 18 months (pbon N 0.05), whereas the 24 month age groupshowed levels that were signiﬁcantly higher than all other age groups
(pbon b 0.001).
3.2. Changes in the soluble Aβ1–40 and Aβ1–42 content and the Aβ1–42/Aβ1–40
ratio
In addition to the global Aβ1–x analysis, we also speciﬁcally investi-
gated the levels of soluble Aβ1–40 and Aβ1–42. As with the Aβ1–x analysis,
the values of theWT groupweremostly situated below the lower detec-
tion limit and a clear difference could be observed between the WT and
HET in all age groups for both Aβ1–40 and Aβ1–42 (p b 0.001).When com-
paring the Aβ1–40 levels for HET between the various age groups
(Fig. 1B), the youngest age group displayed signiﬁcantly lower levels
than all other ages (pbon b 0.001). The levels of the 24 month group, on
the other hand, were signiﬁcantly elevated compared to all other ages
(pbon b 0.001). No statistically signiﬁcant differences could be found be-
tween the Aβ1–40 levels of the 3, 6, 12, and 18-month-old group. The 3-
month-old group did show slightly lower levels than the 12-month-old
group (pbon = 0.020) and the 18-month-old values were also found to
be lower than the levels at 6 months (pbon = 0.023) and 12 months
(pbon = 0.013), but these differences did not reach the Bonferroni-
corrected post hoc signiﬁcance level of 0.0033. The Aβ1–42 levels in the
APP23 model seemed to remain constant from 1.5 to 12 months on
(Fig. 1C, pbon N 0.050). At 18 and 24 months, the levels appeared to be
signiﬁcantly elevated compared to the younger ages (pbon b 0.001), but
no difference was found between the two oldest age groups (pbon =
0.278). Finally, we also analyzed how the changes in the individual levels
of Aβ1–40 and Aβ1–42 affect the ratio between the two Aβ variants
(Fig. 1D). In most age groups, the amount of Aβ1–42 was about 10% of
the amount of Aβ1–40. However, at the age of 1.5 and 18months, a signif-
icant spike in the Aβ1–42/Aβ1–40 ratio could be observed (pbon b 0.001)
and the Aβ1–42 levels reached around 20% of the Aβ1–40 levels.
3.3. Quantitative comparison of APP, CTFβ, and Aβ levels between age
groups
In order to further investigate the underlying causes for the changes in
Aβ levels, we explored whether these changes were also reﬂected in the
levels of the precursor protein for Aβ and in the levels of CTFβ, an inter-
mediary product in the production of Aβ. The two characteristic bands
of immature andmature (or post-translationally modiﬁed) APP were an-
alyzed together to obtain the total level of full-length APP. Control WT
samples were run on each blot, but as they showed no bands for human
APP or CTFβ, they were not included in the statistical analysis. All protein
levels were determined as the relative percentage compared to the pro-
tein level at 1.5 months. Overall, a signiﬁcant difference could be found
for the relative APP levels between the various age groups (Fig. 2A
and 2B, pbon = 0.002). Between the age of 6 and 24 months,
however, the levels remained constant (pbon N 0.05). At 1.5 months, sig-
niﬁcantly lower APP levels were observed compared to the levels at 18
and 24 months of age (pbon b 0.001). The levels at 1.5 months were also
slightly lower than at 6 (pbon = 0.006) and 12 months (pbon = 0.042),
but these differences did not reach the 0.0033 Bonferroni-corrected sig-
niﬁcance level. Similar lower levels could be observed between the 3-
month-old group and6 (pbon=0.007), 18 (pbon=0.007), and24months
groups (pbon = 0.007). No difference was found between the 1.5 and the
3 months group (pbon = 0.404). The CTFβ levels displayed a clear evolu-
tion in time (Fig. 3A and 3B, p b 0.001). CTFβ content was found to be
signiﬁcantly lower in the youngest age group compared to all other
ages (pbon b 0.001), except for 3 months (pbon = 0.083). Between 3 and
12 months, no changes in CTFβ levels could be observed (pbon N 0.05).
At 18 months, a signiﬁcant rise in CTFβ could be observed compared to
all younger ages (pbon b 0.0033). This rise in CTFβ continues, resulting
in even higher levels at 24 months (pbon b 0.001). Finally, we also ob-
served that the rise in CTFβ levels at 18 and 24months coincideswith ap-
pearance of Aβmonomer and low n-oligomer bands on theWestern blot
Fig. 1. Results of the ELISA measurements of various Aβ species in heterozygous APP23 mice ranging from 1.5 to 24 months in age. Group medians are displayed in the graphs (error bars:
interquartile range). (A) Comparison of Aβ1–x concentrations between the various age groups: 1.5 (n = 9), 3 (n = 10), 6 (n = 10), 12 (n = 11), 18 (n = 10), and 24 months (n = 8).
(B) Comparison of Aβ1–40 concentrations between the various age groups: 1.5 (n = 9), 3 (n = 10), 6 (n = 10), 12 (n = 11), 18 (n = 10), and 24 months (n = 9). (C) Comparison of
Aβ1–42 concentrations between the various age groups: 1.5 (n=9), 3 (n=10), 6 (n=9), 12 (n=11), 18 (n=10), and24months (n=9). (D) Comparison of Aβ1–42/Aβ1−40 ratio between
the various age groups: 1.5 (n=9), 3 (n=10), 6 (n=9), 12 (n=11), 18 (n=10), and 24months (n=9). Symbols indicate a signiﬁcant difference compared to speciﬁc age groups (post
hoc Mann–Whitney with Bonferroni correction for multiple comparisons; signiﬁcance level p b 0.0033). Solid squares = compared to all younger age groups, asterisks = compared to
6,12,18, and 24 months, open circles = compared to 1.5, 3, 6, and 12 months, open squares = compared to 3, 6, 12, and 24 months. Abbreviations: Aβ, amyloid-beta.
Fig. 2. Results fromWestern blot analysis of full-length APP levels in heterozygous APP23
mice ranging from1.5 to 24months in age. (A) Image displayingWestern blot results from
heterozygous mice of all age groups. Two wild-type samples were run as negative con-
trols. (B) Graph displaying relative quantiﬁcation of APP levels compared to the APP
level of 1.5-month-old APP23 mice (group medians with interquartile range error bars,
n= 9 for the 12months group and n=8 for all other age groups). Solid triangles indicate
signiﬁcantly lower APP levels compared to 18 and 24 months (post hoc Mann–Whitney
with Bonferroni correction for multiple comparisons; signiﬁcance level p b 0.0033).
Abbreviations: m-APP, mature amyloid precursor protein; im-APP, immature amyloid
precursor protein; HET, heterozygous; WT, wild type.
Fig. 3. Results fromWestern blot analysis of CTFβ, Aβmonomer, and low n-oligomer levels
in heterozygous APP23 mice ranging from 1.5 to 24 months in age. (A) Image displaying
Western blot results from heterozygous mice of all age groups. Two wild-type samples
were run as negative controls. (B) Graph displaying relative quantiﬁcation of CTFβ levels
compared to the CTFβ level of 1.5-month-oldAPP23mice (groupmedianswith interquartile
range error bars n=9 for the 12months group and n=8 for all other age groups). Symbols
indicate a signiﬁcant difference compared to speciﬁc age groups (post hoc Mann–Whitney
with Bonferroni correction for multiple comparisons; signiﬁcance level p b 0.0033).
Solid squares = compared to all younger age groups, asterisks = compared to 6,12,18,
and 24 months, open triangles = compared to 1.5, 3, 6, 12, and 24 months. Abbreviations:
Aβ, amyloid-beta; CTFβ, C-terminal fragment beta; HET, heterozygous; WT, wild type.
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Fig. 4. Results fromWestern blot analysis of PS1 levels in heterozygous APP23 mice and
wild-type littermates ranging from 1.5 to 24months in age. (A) Image displayingWestern
blot results from HET and WTmice of all age groups. (B) Graph displaying relative quan-
tiﬁcation of PS1 levels compared to the PS1 level of 1.5-month-old WT mice (group me-
dians with interquartile range error bars, n = 7 for all test groups). Abbreviations: PS1,
presenilin 1; HET, heterozygous; WT, wild type.
Fig. 5. Results fromWestern blot analysis of BACE1 levels in heterozygous APP23mice and
wild-type littermates ranging from 1.5 to 24months in age. (A) Image displayingWestern
blot results from HET and WT mice of all age groups. (B) Graph displaying relative quan-
tiﬁcation of BACE1 levels compared to the BACE1 level of 1.5-month-old WT mice (group
medians with interquartile range error bars, n = 7 for all test groups). Abbreviations:
BACE1, beta-site APP-cleaving enzyme 1; HET, heterozygous; WT, wild type.
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quantiﬁcation was performed.
3.4. Evaluating PS1 and BACE1 levels between different age groups
In the end, we investigated whether the observed changes in Aβ
levels correlated to changes in the levels of proteins playing a key role
in the production of Aβ, PS1, and BACE1. We determined PS1 (Fig. 4)
and BACE1 (Fig. 5) levels in both WT and HET animals of each age
group and expressed them as relative percentages compared to the pro-
tein level of WT mice at the age of 1.5 months. Overall, none of the var-
ious age groups displayed differences between the HET andWT for both
PS1 (p N 0.05) and BACE1 (p N 0.05). No evolution over time could be
found in the levels of PS1 and BACE1 for both WT (pbon N 0.05) and
HET (pbon N 0.05) animals.
4. Discussion
The aim of this study was to investigate the evolution of soluble Aβ
levels with increasing age in the APP23 mouse model. The overall Aβ
levels displayed a speciﬁc pattern with an initial buildup in the soluble
Aβ levels, followed by more or less constant levels up to 18 months
and ending in a substantial increase at an older age. In general, the evo-
lution in Aβ1–40 levels appeared to follow a pattern similar to the Aβ1–x
pattern. The Aβ1–42 levels deviated from the global pattern as they did
not show the initial increase in the younger age groups and a signiﬁcant
increase in Aβ1–42 can already be observed at 18months. These ﬁndings
are in line with the results found in several other studies regarding the
Aβ pathology in APP23 and other mouse models [38,40–42]. While the
pattern differs signiﬁcantly from the pattern that has been observed in
the APPPS1 double mouse model [40], it shows a lot of similarities
with previous ﬁndings in APP23 and other APP-mutation models. The
APPPS1 model, which contains a mutation in the APP gene, as well as
in the PS1 gene, displays a continuous increase in Aβ levels [40].
APP23, APP24, and APP51 mice, on the other hand, all appear to share
the pronounced jump in Aβ levels at an older age [40,41]. The steady
state in soluble Aβ levels, however, could not be conﬁrmed by these
studies. One of the studies already showed modest increase starting at
the age of 8 months [41], but this study did not focus solely on soluble
Aβ. The researchers used the formic acid soluble fraction, which alsocontains the Aβ present in brain plaques. As the APP23 model starts to
develop plaques from the age of 6 months onwards [37,38,41], the ob-
served rise in Aβ could be due to solubilized Aβ from plaques. Another
study did focus on soluble Aβ but did not include ages between 6 and
16 months. As such, the steady state around 12 months could not be
veriﬁed [40]. As the other studies also did not include the 1.5-month
age group, no comparison could be made for the initial rise in overall
Aβ and Aβ1–40. The absence of this increase in the Aβ1–42 levels has
been previously observed [38]. With regard to the increase in soluble
Aβ1–42 at 18 months, one research group found a similar increase at
16 months, but this group also found a signiﬁcant increase in Aβ1–40 at
this age. Despite the difference in the absolute measurement of Aβ1–40
levels, they did ﬁnd a similar increase in the Aβ1–42/Aβ1–40 ratio at 16
months. The difference in the Aβ1–40 measurement could be due to dif-
ferences in the protein extraction method, the breeding colony, or the
selected subpopulation of mice. Additionally, since the Aβ1–42/Aβ1–40
ratio has been shown to inﬂuence theAβ aggregation kinetics and an in-
creased ratio has been linked tomore severe AD pathology [43–46], this
could actually prove to be the more pathologically signiﬁcant parame-
ter. In general, our results seem to suggest that Aβ1–42 levels appear to
rise faster than Aβ1–40 leading to an increase in the Aβ1–42/Aβ1–40 ratio
at 1.5 and 18 months. The fact that Aβ1–42 and Aβ1–40 levels can change
independently from each other is a curious and relatively unexpected
ﬁnding. Unlike other mutations, the mutation in the APP23 model
does not cause γ-secretase to preferentially cleave at the Aβ1–42 site.
The change in ratio may, therefore, not be due to differences in the pro-
duction of the Aβ species, but rather a consequence of variability in ag-
gregation, degradation, and/or removal. Interestingly, the increased
ratios precede distinct cognitive deterioration in the APP23 model.
After the ﬁrst spike at 1.5 months, cognitive deterioration occurs, and
at the next time point (3 months), cognitive deﬁcits can be observed
in complex cognitive tasks, like theMorriswatermaze [38,47]. Applying
simpler tasks, like small-sizedMorris watermazes or nonspatial passive
avoidance learning, deﬁcits in lower order cognitive functions can be
detected at the age of 25 months [47], the ﬁrst time point after the
second increase in the Aβ1–42/Aβ1–40 ratio at 18 months. During the
steady-state period between the two observed increases in the ratio,
no changes in cognitive performance have been observed, but the peri-
od does coincide with the appearance of plaques and an increase in
plaque load and insoluble Aβ [37,38,48]. This is in agreement with the
theory that soluble Aβ is responsible for the cognitive deﬁcits and not
110 L. Janssen et al. / Biochimica et Biophysica Acta 1862 (2016) 105–112the Aβ plaques [29,34,49]. In fact, these ﬁndings appear to support the
hypothesis that the formation of plaques could have a protective effect
by sequestering free, soluble Aβ [50]. It is probable that, while Aβ is con-
tinuously produced in excess, the steady-state in the pool of soluble Aβ
between3 and 12months is initiallymaintained by diverting Aβ toward
the insoluble pool, resulting in the observed increase in plaque load
from 6 months on. With the second increase in the Aβ1–42/Aβ1–40
ratio, a signiﬁcant increase in plaques has also been reported [41,42].
We opted to use only males in this study, as we wanted to compare
our results with previous behavioral and cognitive experiments
where exclusively males were used to avoid inﬂuences of ﬂuctuating
hormonal levels. In general, conﬂicting ﬁndings have been published
regarding gender differences in AD pathology. Where a gender effect
has been reported for certain aspects of AD pathology (e.g. cognitive
performance, atrophy) [reviewed in 51], no such effects have been
found for others. For instance, a recent multicenter study showed
no gender differences in CSF biomarker levels, including Aβ1–42
[52]. Perhaps more importantly, a study in the 5xFAD mouse model
showed no effect of gender on APP, BACE, and Aβ levels [53]. Togeth-
er, these ﬁndings might suggest that the Aβ-producing pathway is
not affected by gender and that our results could possibly be extrap-
olated to female APP23 mice as well.
In this study, we also wanted to explore the possible causes for the
observed changes in Aβ levels. In general, the increase in the amount
of soluble of Aβ in the brain can be caused by an increase in production,
a decrease in clearance, or a combination of both. Here we investigated
the concentration of four key proteins from the Aβ production pathway:
APP, CTFβ, PS1, and BACE. APP showed slightly lower levels at a younger
age, but the levels remained relatively stable in mature mice. The initial
evolution could of course simply be part of the brain maturation process
[54]. Alterations due to brain development could also contribute to the
changes in Aβ levels at younger ages. However, these developmental
changes do not provide an explanation for the second increase in Aβ
levels at a later age. CTFβ, an intermediary product in the production of
Aβ, does display the secondary increase at old age, as well as the initial
buildup. No signiﬁcant alterations could be found in the PS1 and BACE1
levels. In the past, studies have found that BACE activity can be increased
with age and that this increase in activity is not always reﬂected by an el-
evated protein level [55,56]. However, so far no data exist about the evo-
lution in BACE activity in APP23 model. While we cannot exclude the
possibility that the activity of β- and γ-secretase is altered by post-
translational modiﬁcations or other mechanisms, our study shows no
clear correlation between the PS1 and BACE1 levels and the changes in
Aβ concentrations. The APP levels, on the other hand, may provide
some insight into the mechanism behind the initial increase in Aβ and
CTFβ, but fail to explain the changes in Aβ and CTFβ levels at 18 months
and older. The rise in concentration of these proteins and the appearance
of Aβmonomers and low n-oligomers in the membrane-bound fraction
is, therefore, possibly due to decreased clearance. This decrease in Aβ
clearance has actually already been reported in several studies with AD
patients [57–60]. In the APP23 mouse model a recent, in vivo PET imag-
ing study also showed increased tracer retention at advanced ages [61].
In fact, while a general slower protein turnover has been reported with
increasing age (~30–40% slower), it was recently established that the
Aβ turnover actually slows by 60% [57]. Several of the mechanisms in-
volved in Aβ clearance, like the glymphatic system, proteolytic degrada-
tion, and autophagy, have also been found to show age-dependent
alterations [62–64]. Together, these ﬁndings suggest that alterations in
the clearance of Aβ could play an important part in AD pathology, espe-
cially in sporadic cases of ADwhere no clear genetic evidence for changes
in Aβ production is present. Until now, research has put a lot of emphasis
on determining protein levels. These levels, however, are the result of a
complex interaction between the processes responsible for production
and removal. Therefore, future research should maybe focus more on
the age-related changes in Aβ turnover and kinetics, exploring produc-
tion and removal simultaneously where possible.5. Conclusion
In this study,we found a distinct age-related pattern in the evolution
of soluble Aβ levels in the APP23 mouse model. While this model al-
ready displays cognitive deﬁcits and plaque pathology at a relatively
early age due to the human APP construct and the initial buildup of
human Aβ, we discovered a surge in Aβ levels at a later age which
shows interesting similarities to alterations in Aβ levels and Aβ clear-
ance observed in human patients. Owing to practical considerations
and the increased demand in time and resources these older age groups
are often underrepresented in experiments. However, our research
shows that these age groups could provide valuable insights into AD pa-
thology and its connection to aging, for EOAD as well as sporadic AD.
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